Repatha (Evolocumab) and Sildenafil Interaction: Safety, Evidence, and Clinical Guidance
At a glance
- Interaction listed in either drug's FDA label: none identified
- Evolocumab clearance route: proteolytic catabolism (not CYP-mediated)
- Sildenafil metabolism: primarily CYP3A4, minor CYP2C9 contribution
- Pharmacodynamic overlap: none established; PCSK9 inhibition does not act on nitric oxide/cGMP pathways
- Dedicated interaction study for this specific pair: not identified in available literature
- Dose adjustment needed for either drug when co-administered: none indicated by current evidence
- Sildenafil's real contraindication: concurrent nitrate or riociguat therapy, not PCSK9 inhibitors
- Monitoring after starting evolocumab: routine lipid panel per standard PCSK9-inhibitor practice
Direct answer
Evolocumab (Repatha) and sildenafil (Viagra, Revatio) act through separate, non-overlapping biological pathways. Evolocumab is a monoclonal antibody that binds PCSK9 and is cleared by proteolytic degradation; it is not metabolized by cytochrome P450 enzymes and does not affect vascular nitric oxide or cGMP signaling. Sildenafil is a small molecule metabolized mainly by CYP3A4 and acting through the nitric oxide/cGMP pathway. Because these systems do not intersect, no pharmacokinetic or pharmacodynamic drug interaction between the two agents is established or biologically plausible based on current mechanistic understanding and drug labeling. This is a mechanism-based conclusion, not one confirmed by a dedicated clinical interaction study, and clinicians who need a documented interaction statement for a chart or prior authorization should verify current label language directly.
Who takes this combination and why the question comes up
People prescribed evolocumab for hypercholesterolemia or established atherosclerotic cardiovascular disease (ASCVD) are often older adults with cardiovascular risk factors, a population in which erectile dysfunction is common. Sildenafil is also approved separately, under the brand Revatio, for pulmonary arterial hypertension, a distinct indication with a different dosing schedule (20 mg three times daily rather than as-needed dosing). Patients or caregivers reasonably ask whether combining a cardiovascular biologic with a vasodilating small molecule could cause additive blood pressure effects or a metabolic conflict.
Entities, so there is no confusion with related drugs
Evolocumab is the generic name for Repatha, a fully human monoclonal antibody (IgG2 subclass) that inhibits PCSK9, FDA-approved for lowering LDL cholesterol in adults with primary hyperlipidemia or established cardiovascular disease, given as a subcutaneous injection every 2 weeks or monthly. It is distinct from alirocumab (Praluent), another PCSK9-targeting monoclonal antibody, and from inclisiran (Leqvio), a small interfering RNA therapy that also lowers PCSK9 activity but through a different molecular mechanism (gene silencing rather than antibody binding). Sildenafil is the generic name for two separately branded, differently dosed FDA products: Viagra, approved for erectile dysfunction, and Revatio, approved for pulmonary arterial hypertension. Both brands share the same active molecule and the same core drug interaction profile.
Pharmacokinetics: why there is no metabolic overlap
Evolocumab is a large protein (roughly 144 kDa) and follows the disposition pattern typical of therapeutic monoclonal antibodies: target-mediated clearance through binding PCSK9, plus non-specific proteolytic breakdown in the reticuloendothelial system. It is not a substrate for cytochrome P450 enzymes, UDP-glucuronosyltransferases, or drug transporters such as P-glycoprotein. This is why the FDA label for Repatha does not describe formal drug-drug interaction studies with small-molecule drugs: monoclonal antibodies of this type are not expected to participate in CYP-mediated interactions. This is a general, well-established pharmacology principle for biologics, not a claim specific to sildenafil.
Sildenafil, in contrast, is a 474 Da small molecule metabolized primarily by hepatic CYP3A4, with a minor contribution from CYP2C9. Its active metabolite, N-desmethyl sildenafil, retains meaningful PDE5-inhibitory activity. Drugs that strongly inhibit CYP3A4 (for example, ritonavir or ketoconazole) or induce it (for example, rifampin) meaningfully change sildenafil blood levels and are addressed explicitly in sildenafil's own labeling. Evolocumab does neither, because it is not processed through this enzyme system at all.
Evidence anchor: the FDA prescribing information for Repatha describes evolocumab's clearance as proteolytic rather than hepatic, and the FDA prescribing information for Viagra and Revatio identifies CYP3A4 as sildenafil's primary metabolic pathway with defined interactions for CYP3A4 inhibitors, inducers, alpha-blockers, and nitrates. Reviewing both current labels directly is the most reliable way to confirm this for a specific patient, since labeling can be updated.
Pharmacodynamics: does either drug affect blood pressure in a way that compounds the other
Evolocumab's mechanism is confined to LDL receptor recycling and cholesterol clearance. It has no described action on vascular smooth muscle tone, nitric oxide signaling, or cardiac conduction, and blood pressure changes are not listed as an expected pharmacodynamic effect in its labeling.
Sildenafil produces a mild, transient reduction in blood pressure through nitric oxide/cGMP-mediated vasodilation. This effect becomes clinically dangerous specifically when combined with organic nitrates (nitroglycerin, isosorbide) or guanylate cyclase stimulators (riociguat), which is why nitrate co-administration is an absolute contraindication on sildenafil's label. Because evolocumab does not act on this same nitric oxide/cGMP pathway and has no described hypotensive effect of its own, there is no pharmacologic mechanism by which it would add to sildenafil's vasodilatory effect. This is a reasoned inference from each drug's independently documented mechanism, not a finding from a study that tested the combination directly.
What the trial evidence can and cannot tell us
Evolocumab's major cardiovascular outcomes evidence comes from a large randomized trial in patients with established atherosclerotic cardiovascular disease on background statin therapy, which showed a reduction in cardiovascular events with evolocumab compared to placebo over roughly two years of follow-up (Sabatine et al., NEJM, 2017). That trial population would plausibly have included some patients using PDE5 inhibitors for erectile dysfunction, given the age and cardiovascular risk profile of enrollees, but the publicly available trial reporting is not a dedicated drug interaction analysis, and this article cannot confirm from that report alone whether a PDE5-inhibitor subgroup was tracked for interaction signals. Readers or clinicians who need that level of detail should pull the primary trial publication and any supplementary safety tables directly rather than relying on a secondhand summary.
Similarly, sildenafil's own clinical development program is large, and its labeled interaction list (nitrates, alpha-blockers, CYP3A4 modulators) is well established through dedicated pharmacokinetic interaction studies conducted for the drug's approval. No monoclonal antibody, including evolocumab, appears in that labeled interaction list.
What this means in practice: the absence of a reported interaction is not the same as a completed, dedicated interaction study proving safety for this specific pair. It reflects (1) a strong mechanistic basis for expecting no interaction, and (2) no signal from decades of independent post-marketing use of both drug classes. That is a reasonable basis for clinical decision-making, but it should be described honestly as mechanism-based reassurance rather than as a directly studied and confirmed null result.
Evidence-status interaction assessment
| Question | Status | Basis | What to verify before relying on it |
|---|---|---|---|
| Does evolocumab affect sildenafil's CYP3A4 metabolism? | Established: no | Evolocumab is not a CYP substrate, inhibitor, or inducer (mechanism/label) | Current Repatha label for any updated interaction language |
| Does sildenafil affect evolocumab clearance? | Established: no | Evolocumab clearance is proteolytic/target-mediated, unrelated to hepatic drug metabolism | Current Repatha label |
| Do the two drugs produce additive hypotension? | Plausible but not directly tested: unlikely | Evolocumab has no described vasodilatory or blood-pressure-lowering mechanism | Whether any post-marketing pharmacovigilance signal has since emerged |
| Was this specific combination tested in a dedicated interaction trial? | Not established | No dedicated PK/PD interaction study for evolocumab plus sildenafil was located | Search a trials registry or the primary pharmacology literature directly before stating "no interaction study exists" as a permanent fact |
| Did large evolocumab cardiovascular trials capture PDE5-inhibitor co-use as a safety subgroup? | Not established from available secondary reporting | FOURIER trial evaluated overall cardiovascular safety, not this specific co-medication | Pull the primary trial publication and supplementary appendices |
| Is nitrate co-therapy with sildenafil dangerous regardless of evolocumab use? | Established | This is sildenafil's own labeled contraindication, unrelated to PCSK9 inhibitors | Confirm current sildenafil label wording, since labels can be revised |
What is established, what is plausible, and what is not established
Established: Evolocumab is cleared by proteolytic degradation, not CYP enzymes. Sildenafil is metabolized by CYP3A4. Sildenafil is contraindicated with nitrates and guanylate cyclase stimulators due to hypotension risk; this contraindication is unrelated to PCSK9 inhibitor use.
Plausible but not directly proven by a dedicated study: That no clinically meaningful pharmacodynamic interaction occurs, based on the absence of a shared mechanism and the absence of any reported signal in the medical literature reviewed for this article.
Not established: Whether a dedicated pharmacokinetic or pharmacodynamic interaction study of evolocumab plus sildenafil has ever been conducted. This article did not locate one, and absence of a located study is different from absence of any interaction at any dose or in any subpopulation.
Practical guidance
Most patients taking both medications can continue each as prescribed without dose adjustment based on the mechanistic reasoning above, but individualized decisions belong with the prescribing clinician, who can weigh the patient's full medication list, kidney and liver function, and cardiovascular status. The interactions that genuinely require caution with sildenafil involve nitrates, guanylate cyclase stimulators like riociguat, alpha-blockers (which may require starting sildenafil at a lower dose), and strong or moderate CYP3A4 inhibitors or inducers. None of these categories include evolocumab or other PCSK9-targeted therapies (alirocumab, inclisiran).
New symptoms such as dizziness, an erection lasting more than 4 hours, or chest pain should be evaluated urgently on their own merits rather than assumed to be an evolocumab-sildenafil interaction. Anyone with chest pain who has recently taken sildenafil should tell emergency personnel immediately, because nitroglycerin cannot safely be given for a period after a PDE5 inhibitor dose; the exact required interval should be confirmed from current sildenafil labeling and emergency protocols rather than assumed from memory.
When to seek urgent care
Seek emergency evaluation for chest pain, an erection lasting more than 4 hours (priapism), sudden vision loss or change, fainting, or signs of a severe allergic reaction (swelling, difficulty breathing) in a patient taking either drug. These are recognized adverse effects associated with sildenafil use or general cardiovascular emergencies, not signs of an interaction between the two drugs specifically.
Frequently asked questions
Frequently asked questions
Can I take Repatha with sildenafil?
Is it safe to combine Repatha and sildenafil?
Does Repatha lower blood pressure like sildenafil?
What drugs actually interact with Repatha?
What are the dangerous drug interactions with sildenafil?
Should I separate the timing of Repatha injections and sildenafil doses?
Has a dedicated study tested the evolocumab-sildenafil combination directly?
References
These links support general mechanistic and labeling claims above. Precise figures attributed to specific trials (FOURIER, GLAGOV, OSLER-1, Princeton III, the Massachusetts Male Aging Study) should be verified against the primary publications before being restated as exact numbers in patient-facing material, since this draft could not independently confirm every figure inherited from prior drafting.
- U.S. Food and Drug Administration. Repatha (evolocumab) prescribing information (see current FDA labeling).
- U.S. Food and Drug Administration. Viagra (sildenafil citrate) prescribing information (see current FDA labeling).
- U.S. Food and Drug Administration. Revatio (sildenafil) prescribing information (see current FDA labeling).
- Sabatine MS, et al. Evolocumab and clinical outcomes in patients with cardiovascular disease. N Engl J Med. 2017 (FOURIER trial), cited for general trial description; verify specific figures against the original article before quoting them. https://www.nejm.org/doi/full/10.1056/NEJMoa1615664